

UNITED STATES PARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.	
	08/849,54	3 06/10/	97 CHAM		K	7676-46(9710
Г	33M1/0121			٦	EXAMINER	
	PANITCH S		COBS & NADEL		0,K	#5
	36TH FLOO				ART UNIT	PAPER NUMBER
	PHILADELP	HIA PA 191	03		3308	
					DATE MAILED:	01/21/98

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

PTO-90C (REV. 2/95) 1 - File Copy

Office Action Summary

Application No. 08/849,543

0

Applicant(s)

Cham

Examiner

Group Art Unit
3308

X Responsive to communication(s) filed on <u>Jun 10, 1997</u>					
☐ This action is FINAL .					
Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quay/1035 C.D. 11; 453 O.G. 213.					
A shortened statutory period for response to this action is set to expire3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).					
Disposition of Claim					
Of the above, claim(s) is/are withdrawn from consideration					
X Claim(s) <u>5-7</u> is/are allowed.					
Claim(s) is/are objected to.					
Claims are subject to restriction or election requirement.					
Application Papers See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948. The drawing(s) filed on is/are objected to by the Examiner. The proposed drawing correction, filed on is approved					
received in Application No. (Series Code/Serial Number)					
☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)). *Certified copies not received:					
Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).					
Attachment(s) Notice of References Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Paper No(s)4 Interview Summary, PTO-413 Notice of Draftsperson's Patent Drawing Review, PTO-948 Notice of Informal Patent Application, PTO-152					
SEE OFFICE ACTION ON THE FOLLOWING PAGES					

Art Unit: 3308

Information Disclosure Statement

1. The information disclosure statement filed 6/10/97 fails to comply with 37 CFR 1.98(a)(3) because it does not include a concise explanation of the relevance, as it is presently understood by the individual designated in 37 CFR 1.56(c) most knowledgeable about the content of the information, of each patent listed that is not in the English language (DE 33 10 263 A1). They have been placed in the application file, but the information referred to therein has not been considered.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 3. Claims 1, 2, and 15-22 are rejected under 35 U.S.C. 102(b) as being anticipated by Cham (4,895,558).

In regards to claim 1 and 2:

Applicant claims a method for removal of cholesterol, triglycerides and other lipids from plasma and serum comprising withdrawing blood, separating the blood, and mixing with a solvent which extracts lipids after which the blood is returned to the subject. Such lipid apheresis or LDL apheresis is known in the art. Cham discloses the method of LDL apheresis comprising drawing blood, separating the plasma, delipidating the plasma with a lipid solvent and remixing the

Art Unit: 3308

dilipidated with the red blood cell for re-introduction to the body. The extraction solvent in Cham is substantially removed by washing with a second solvent (ether).

In regards to Claim 15-22:

Such characteristics are inherent.

Claim Rejections - 35 USC § 103

- 4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 5. Claims 8-14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cham (4,895,558) in view of Rauh et al (5,401,415).

In regards to Claims 8-11, 13, and 14:

Cham does not disclose the use of an absorbent specific for the extraction solvent.

However, Rauh discloses the use of "glass beads" to extract the solvented lipids which are considered to be Applicant's "sintered spheres". Furthermore, it is stated in Rauh the use for the adsorption methods in apheresis systems (col. 1, lines 47-64). The beads provide the physical filtration system for the lipids which does not require the separation of two aqueous components. It would have been obvious to one of ordinary skill in the art to put glass bead for extraction of lipids in the Cham device to facilitate the process of filtration without the need to separate two

Art Unit: 3308

aqueous components. Rauh's sintered spheres are considered to have the characteristics of features as claimed in Claims 9-11, 13, 14

In regards to Claim 12:

Cham does not disclose the dilipidated fraction to pass through the absorbent at least twice as claimed in Claim 12. However, such method is obvious. The Applicant undoubtedly provides multiplied effects when absorbent method is used twice, but it is not the type of innovation for which a patent monopoly is to be granted. It is difficult to conceive of a more obvious method of multiplying the effect than by passing it through twice.

6. Claims 3 and 4 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cham (4,895,558).

In regards to Claim 3:

Cham does not disclose washing the solvent 4 times as claimed in Claim 3. However, such method is obvious. The Applicant undoubtedly provides multiplied effects when washing multiple times, but it is not the type of innovation for which a patent monopoly is to be granted. It is difficult to conceive of a more obvious method of multiplying the effect than by washing it more than once.

In regards to Claim 4:

Cham does not disclose the use of the use of solvent diethyl ether as claimed in Claim 4, but rather di-isopropylether (DIPE). The polar characteristics of the solvents are very similar and

Art Unit: 3308

the applicant does not disclose the criticality for the use of diethyl ether. Therefore, it would have been obvious matter of design choice to employ such use of diethethyl ether on the Cham device since the applicant has not disclosed that such solves any stated problem or is for any particular purpose, and it appears the method would work equally well with various other solvents.

Allowable Subject Matter

- 7. Claims 5-7 are allowed.
- 8. The following is a statement of reasons for the indication of allowable subject matter:

The use of the beads which has a density substantially mid-way between the density of the fraction and the density of the solvent with the other claimed methods is patentably distinct and it appears that no other prior art teach of such use of beads. It is considered critical to isolate the fractions.

Art Unit: 3308

Conclusion

9. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Rosskopf et al (4,648,974), Seidel et al (4,908,354), Seidel et al (4,935,204), Davidson (5,279,540), Filip (5,424,068), and Boos et al (5,679,260).

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ki O whose telephone number is (703) 308-2681.

JOHN G. WEISS SUPERVISORY PATENT EXAMINER GROUP 3300

fleth.

Ki O

January 14, 1998

Long O